Immunotherapy

NATIONAL HARBOR, Md. — Allogeneic activated natural killer cell therapy resulted in some antitumor activity with no serious side effects in patients with metastatic Merkel cell carcinoma, according to the results of a phase 2 study presented at the SITC Annual Meeting.

HOUSTON — Food allergies affect 6% to 8% of children and 2% to 3% of adults, according to a presentation at the American College of Asthma, Allergy & Immunology Scientific Meeting.

NATIONAL HARBOR, Md. — An investigational anti-CD73 antibody appeared safe and demonstrated promising antitumor activity among patients with advanced cancers, according to phase 1/1b trial data presented at Society for Immunotherapy of Cancer Annual Meeting.

Thomas Gajewski, MD, PhD, will receive this year's ESMO Award for Immuno-Oncology.

The University of Texas MD Anderson Cancer Center has announced a new research and development agreement with partner Ziopharm Oncology for the development of neoantigen-specific T-cell receptors, a cell-based therapy used to treat various forms of cancer.

CHICAGO — In patients with advanced cutaneous squamous cell carcinoma, a multidisciplinary discussion on treatment options should include oncologists, radiation oncologists and the primary care physician in weighing risks and benefits to various approaches, according to Todd Schlesinger, MD, FAAD, FASMS, medical director at Dermatology and Laser Center of Charleston.

The FDA has granted its regenerative medicine advanced therapy designation to CT053, a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma.

The FDA has granted its regenerative medicine advanced therapy designation to CT053, a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Phase 1 study of adoptive immunotherapy with CD8+ and CD4+ memory T cells transduced to express an HA-1-specific T cell receptor for children and adults with recurrent acute leukemia after allogeneic hematopoietic stem cell transplantation.

Cameron Turtle, MD, PhD, a pioneer in the field of chimeric antigen receptor T-cell therapy, has been honored as the inaugural recipient of the Anderson Family Endowed Chair for Immunotherapy at Fred Hutchinson Cancer Research Center.